Longevity
NMN and NR both raise blood NAD+ in short human trials; no head-to-head study exists and functional benefits are unproven. Trial doses, safety and what is known about each.
Key takeaways
Both NMN and NR flood supplement shelves with promises of restored energy, reversed aging, and enhanced cellular repair. Both raise NAD+ levels. Both cost more than most supplements in your stack. But they are not the same compound, and the differences matter more than most reviews admit.
This is the comparison guide that cuts through the positioning: what the biochemistry actually shows, what the clinical trials found, and how to decide which—if either—belongs in your protocol.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in over 500 enzymatic reactions. It sits at the center of mitochondrial energy production, DNA repair, and sirtuin activation—the same sirtuins that respond to caloric restriction and fasting.
The problem: NAD+ declines with age. A 2012 analysis in Cell found that NAD+ levels in aged mice were roughly half those in young mice. Human data point the same way, though the size of the decline varies by tissue and by study.
Why it drops: increased NAD+ consumption by DNA-repair enzymes (PARPs) under oxidative stress, reduced activity of biosynthesis enzymes, and declining precursor availability. Supplementing a direct precursor bypasses the slow endogenous synthesis pathway and can rapidly restore circulating NAD+.
Both NMN and NR are that shortcut—but they use slightly different entry points into the same biosynthetic pathway.
NR is a form of vitamin B3. It enters cells via nucleoside transporters and is then phosphorylated to NMN by the NR kinases NRK1 and NRK2, then gets phosphorylated to NMN by NR kinase, and converted to NAD+. It was identified as an NAD+ precursor in a landmark 2004 Cell paper by Bieganowski and Brenner.
Molecular weight: 255 g/mol. It is orally bioavailable and stable in supplement form.
NMN is one step closer to NAD+ in the salvage pathway. For years, a debate existed about whether NMN could enter cells directly or required dephosphorylation to NR first. A 2019 paper by Grozio et al. in Nature Metabolism identified Slc12a8—a dedicated NMN transporter in the gut. This shifted the view: NMN can be absorbed intact and enter cells without converting to NR first.
Molecular weight: 334 g/mol. More complex to synthesize, which historically made it more expensive.
Nicotinamide → (NAMPT) → NMN → NAD+ | NR → (NRK1/2) → NMN → NAD+ | tryptophan feeds NAD+ by a separate de novo route
↑
Both supplements enter here
NR enters at the NR step and gets phosphorylated to NMN before becoming NAD+. NMN enters at the NMN step. In practice, once absorbed, both converge rapidly on the same endpoint.
Trammell et al. (2016, Nature Communications) — First human trial. 12 healthy adults took 100mg, 300mg, or 1000mg NR. Dose-dependent increases in blood NAD+: the 1000mg dose roughly doubled circulating NAD+ levels. No significant adverse effects.
Dellinger et al. (2017, npj Aging) — 120 adults aged 60–80 took NR combined with pterostilbene for 8 weeks; whole-blood NAD+ rose about 40% at the lower dose and about 90% at the higher dose, with no serious adverse events. No effect on blood pressure, body composition, or glucose in this timeframe.
Martens et al. (2018, Nature Communications) — 24 middle-aged and older adults in a crossover design. NR supplementation elevated NAD+ metabolites and reduced a marker of aortic stiffness in a subgroup analysis. First hint of a vascular benefit.
Conze et al. (2019) — Safety and pharmacokinetics in healthy adults. 100mg to 1000mg doses well tolerated. Confirmed dose-dependent NAD+ elevation without meaningful adverse events.
Yoshino et al. (2021, Science) — Arguably the most significant NMN human trial. 25 postmenopausal women with prediabetes or overweight. 250mg NMN daily for 10 weeks. Key finding: NMN increased skeletal muscle insulin sensitivity and improved insulin signaling pathway activity (specifically increased expression of genes involved in muscle remodeling). No systemic effect on body weight, blood pressure, or lipids. This was the first human trial showing NMN affects metabolic tissue function, not just NAD+ levels.
Igarashi et al. (2022, npj Aging) — 42 healthy men aged 65 and over took 250 mg NMN for 12 weeks; blood NAD+ rose and some gait-speed and grip-strength measures improved versus placebo. Biomarkers of inflammation (IL-6, TNF-α) trended down. First trial showing functional physical outcomes.
Kim et al. (2022, Nutrients) — 108 adults aged 65 and over took 250 mg NMN for 12 weeks; afternoon dosing improved a lower-limb function test and reduced drowsiness.
Liao et al. (2021, J Int Soc Sports Nutr) — amateur runners took 300–1,200 mg NMN for 6 weeks; oxygen use at ventilatory threshold improved dose-dependently. Yi et al. (2023, GeroScience) — 80 middle-aged adults took 300–900 mg for 60 days; blood NAD+ rose and six-minute walk distance improved.
| Parameter | NR Evidence | NMN Evidence |
|---|---|---|
| Raises blood NAD+ | ✅ Strong (multiple RCTs) | ✅ Strong (multiple RCTs) |
| Muscle metabolic effects | Limited | ✅ Yoshino 2021 (muscle insulin sensitivity) |
| Physical performance | Minimal direct evidence | ✅ Grip strength, walking speed, aerobic capacity |
| Cardiovascular markers | ✅ Some aortic stiffness data | Minimal |
| Cognitive effects | Emerging | Emerging |
| Safety profile | Good in trials up to 12 weeks | Good in trials up to 12 weeks |
Both raise NAD+. The functional outcomes—what changing that NAD+ level actually does in the body—are more studied in NMN trials to date, though this is partly because NMN trials are more recent and study designs have evolved.
The 2019 Grozio paper was treated as a watershed moment for NMN advocates: if NMN has its own dedicated intestinal transporter, it doesn’t need to convert to NR to be absorbed. The implication: higher concentrations can reach tissues intact and more quickly.
This is plausible, but the clinical significance remains contested. Critics of the Grozio paper note the data was primarily murine (mouse) intestinal cells, not confirmed in human intestinal tissue. A 2020 paper by Schmidt and Brenner argued the transporter data didn’t definitively prove NMN entered circulation intact at relevant doses.
The practical answer: both NR and NMN demonstrably raise blood NAD+ in humans. Whether NMN’s supposed direct cellular entry creates a clinically meaningful difference over NR is still an open question. No well-designed head-to-head trial has directly compared the two at equivalent doses in the same population.
A newer development in NMN formulation is sublingual delivery—dissolving a powder or tablet under the tongue to bypass gut processing entirely. ProHealth and other companies now offer sublingual NMN.
No peer-reviewed human study comparing sublingual with oral NMN pharmacokinetics could be located; claims of faster or higher absorption rest on manufacturer data. Key findings: sublingual delivery produced plasma NMN peaks approximately 40% higher than oral, and the elevation appeared faster (within minutes rather than the 1–2 hour oral absorption window).
Whether peak plasma NMN correlates with better tissue outcomes is still unclear. But if absorption is your concern, sublingual formulations have mechanistic support.
David Sinclair famously takes NMN with resveratrol, citing sirtuin synergy. The theory: resveratrol activates sirtuins, NMN provides the NAD+ fuel they need. The evidence for this specific combination in humans is thin. Resveratrol has poor oral bioavailability unless formulated with fat (micronized or liposomal). See our deep-dive on resveratrol. Short trials have not shown harm from combining them, but the synergy is unproven — and resveratrol has its own interactions (see that article).
Both compounds have strong safety profiles in trials running up to 12 weeks. No serious adverse events have been reported in published human trials.
NR: Occasional reports of flushing (less than standard niacin/B3), nausea, or mild GI upset at doses above 1g/day. These are uncommon and generally mild.
NMN: Similarly clean profile. At very high doses (uncommon in trials), some GI sensitivity. Isolated reports of raised uric acid with high-dose NMN exist; if you have gout or high uric acid, ask a clinician before use.
Long-term safety: Neither compound has long-term human safety data beyond 12 weeks. NMN’s status as a U.S. dietary-supplement ingredient has also been contested by the FDA since 2022. Given the mechanisms (sirtuin activation, PARP activation, DNA repair), theoretical concerns about interactions with cancer biology exist but have not materialized in short-term trials. Individuals with active cancer should discuss with their oncologist.
Drug interactions: Both are metabolized via NAD+ pathways. No confirmed interactions with common medications, but possible theoretical interactions with niacin (additive) or medications that affect NAD+ metabolism.
| NR | NMN | |
|---|---|---|
| 300mg/day | ~$35–55/month | ~$35–60/month |
| 500mg/day | ~$55–80/month | ~$55–90/month |
| 1000mg/day | ~$90–140/month | ~$100–150/month |
Prices have converged significantly as NMN manufacturing scaled up. The early premium for NMN over NR has largely disappeared.
Choose NR if: - You want the longer track record of clinical research (NR was studied in humans first) - You’re focused on cardiovascular or systemic NAD+ elevation as the primary endpoint - You prefer a compound where the absorption mechanism is fully understood
Choose NMN if: - Muscle insulin sensitivity or physical performance is your primary goal (Yoshino and Liao trials specifically) - You want to use the sublingual form for faster absorption - You’re following a protocol from Huberman or Sinclair, who both use NMN
Choose either if: - Your primary goal is simply raising blood NAD+ levels—both do this comparably well
Consider skipping both if: - You’re under 35 with no metabolic dysfunction—the NAD+ decline that drives benefit is most pronounced after 40–50 - Your lifestyle NAD+ depressors (alcohol, sleep deprivation, chronic stress, sedentary) are unaddressed—supplementing around these factors has less impact than fixing them
Most NMN vs NR comparisons either (a) sell one of the compounds, (b) treat them as interchangeable, or (c) ignore the distinction between raising blood NAD+ and actually producing downstream functional outcomes.
The critical nuance: blood NAD+ elevation is a biomarker, not an outcome. Yoshino et al. specifically measured skeletal muscle insulin sensitivity, muscle gene expression, and metabolic function—not just plasma NAD+. If you’re evaluating these supplements by “how much does it raise my NAD+?”, you’re measuring the proxy, not the thing you actually care about.
The better question: what functional outcomes do you want, and which compound has trial evidence specifically for that outcome?
NMN and NR both raise blood NAD+ — a biomarker, not a health outcome. The functional clinical evidence—particularly for muscle metabolism and physical performance—skews toward NMN in more recent trials, though NR has the longer safety record. Head-to-head data doesn’t yet exist.
Trials in adults over 40 have mostly used 250–500 mg NMN or 300–1,000 mg NR daily, usually in the morning; no trial shows a health outcome from that in healthy adults. Talk to a clinician first if you take medication or have a condition. Don’t expect dramatic acute effects—the benefits are long-horizon and difficult to feel. Track objective markers (metabolic panel, physical performance, body composition) rather than subjective energy if you want signal from the experiment.
The science is genuinely promising. Just not as settled as the marketing suggests.
This article is for general education and is not medical advice.
Related
Longevity
The lifting dose linked to longer life is far smaller than a bodybuilding split: pooled cohorts put the lowest mortality at about 30 to 60 minutes of strength work a week, on top of cardio.
Longevity
Many trackers default to 10,000 steps, a figure from a Japanese slogan rather than a trial. Cohort data put the plateau at 6,000 to 8,000 steps a day after 60 and 8,000 to 10,000 before it.
Longevity
Resveratrol is poorly absorbed, and human trials show small, inconsistent metabolic effects — it can even blunt some exercise adaptations. What the trials found and what the red-wine story leaves out.
Readers
Comments
Leave a comment